Latest HCV Stories
However, Recent Changes in Brazil and Argentina are Expected to Drive a Shift in Treatment of HCV Genotype 1 Infections, According to a New Report From Decision Resources BURLINGTON, Mass., May 13, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the majority of hepatitis C virus (HCV) patients in Brazil, Mexico and Argentina rely entirely on government-sponsored medical programs to...
SAN DIEGO, May 7, 2013 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. Through the publication of CEO notes, I seek to provide shareholders and other interested parties with a level of corporate transparency often absent in the microcap marketplace. In recent notes, I reviewed various topics, including emerging opportunities in cancer and the expansion of our government contract program to create a...
Scientists show potential impact of therapy in reducing transmission in UK, Canada and Australia Around 150 million people globally are chronically infected with the hepatitis C virus (HCV) – a major cause of liver disease and the fastest growing cause of liver transplantation and liver cancer. 1 New prevention strategies are urgently required as people are continuing to be infected with HCV. Findings, published in Hepatology, reveal the impact of a new antiviral treatment that could...
- Interferon-free, direct-acting antiviral combination therapy currently in Phase 3 development NORTH CHICAGO, Ill., May 6, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that its investigational direct-acting antiviral (DAA) combination with and without ribavirin for the treatment of genotype 1 (GT1) hepatitis C virus (HCV) infection has been designated as a Breakthrough Therapy by the U.S. Food and Drug Administration (FDA). The designation is based, in part, on...
An All-Oral/Interferon-Free Regimen is One of the Great Unmet Needs in Treatment-Naive HCV, According to a New Report from Decision Resources BURLINGTON, Mass., May 2, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed gastroenterologists in the United States and Europe agree that the percentage of genotype-1 hepatitis C virus (HCV) patients achieving a sustained virological...
Gilead Sciences Leads the Way in Delivering the First All Oral Treatment for HCV NEW YORK, April 26, 2013 /PRNewswire/ -- Citeline®, an Informa business unit, and the world's leading research authority on pharmaceutical clinical trials has just published an exclusive whitepaper examining the current progress towards a remarkable improvement in the medical treatment for HCV. (Logo: http://photos.prnewswire.com/prnh/20120917/NE75453LOGO ) With news of the impending breakthrough in...
BEERSE, Belgium, April 26, 2013 /PRNewswire/ -- - OPTIMIZE study results presented at EASL show similar sustained virological response (SVR12) rates in patients with fibrosis or cirrhosis receiving an INCIVO(R)(telaprevir) combination treatment twice daily versus every eight hours - Janssen Infectious Diseases-Diagnostics BVBA (Janssen), announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
-- STARTVerso(TM)1 data presented in treatment-naïve patients with genotype-1 hepatitis C treated with investigational faldaprevir and pegylated interferon/ribavirin1,2 -- Statistically significant viral cure rates achieved versus placebo plus PegIFN/RBV with similar rates of treatment discontinuation -- The majority of patients qualified for shorter treatment duration of 12 weeks faldaprevir/24...
- STARTVerso(TM)1 data presented in treatment-naive patients with genotype-1 hepatitis C treated with investigational faldaprevir and pegylated interferon/ribavirin RIDGEFIELD, Conn., April 23, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from the pivotal Phase 3 STARTVerso(TM)1 trial of faldaprevir (BI 201335) in combination with pegylated interferon and ribavirin (PegIFN/RBV). In previously untreated patients with genotype-1...
- 96 percent of treatment-naive patients and 93 percent of prior null responders treated with AbbVie's investigational IFN-free, triple-DAA combination therapy achieve SVR24 AMSTERDAM, April 23, 2013 /PRNewswire/ -- (NYSE: ABBV) - Results from "Aviator," AbbVie's phase IIb clinical trial of its investigational direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection, continue to demonstrate high sustained viral response (SVR) rates against genotype 1...
Latest HCV Reference Libraries
Hepatitis C virus (HCV) is an enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. It consists of a core of genetic material surrounded by an icosahedra protective shell of protein. The genome consists of a single open reading frame that is 9600 nucleotide bases long. HCV replication takes several steps. It primarily replicates in the hepatocytes of the liver. It can also reproduce in peripheral blood mononuclear cells. There is a wide variety of genotypes and...
